NAN Share Price Performance
AU$4.14
0.86 (26.22%)
3.5% overvalued intrinsic discount
AU$4.00
Fair Value
Price AU$4.14
AnalystLowTarget AU$4.00
AnalystConsensusTarget AU$4.63
AnalystHighTarget AU$5.43
Fair ValueAU$4.00
Share Pricen/a
Nanosonics Limited Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 42 Fair Values set on narratives written by author
NAN Community Narratives
AN
Fair Value AU$4 3.5% overvalued intrinsic discount
Rising Hospital Cost Containment And Tech Obsolescence Will Erode Profitability
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value AU$4.75 12.8% undervalued intrinsic discount
Automated Disinfection Solutions Will Transform Hospital Safety Worldwide
1users have liked this narrative
1users have commented on this narrative
23users have followed this narrative
AN
Fair Value AU$5.43 23.8% undervalued intrinsic discount
Rising Global Aging And Regulatory Demands Will Accelerate Automated Disinfection
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Global Aging And Regulatory Demands Will Accelerate Automated Disinfection
Key Takeaways Accelerated adoption, regulatory shifts, and digital innovations could drive recurring revenue and margin growth far ahead of current analyst expectations. Strategic manufacturing integration and potential acquisitions may rapidly expand market reach, cost advantages, and diversification within infection prevention.Read more
22
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$5.43
23.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
14.14% p.a.
Profit Margin
20.64%
Future PE
32.7x
Price in 2029
AU$6.57
Rising Hospital Cost Containment And Tech Obsolescence Will Erode Profitability
Key Takeaways Dependence on a single premium product and increased competition from emerging disinfection technologies threaten revenue growth and pricing power. Rising compliance costs, stronger customer bargaining power, and unfavorable currency movements risk compressing margins and hindering global expansion.Read more
38
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$4
3.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
7.49% p.a.
Profit Margin
7.87%
Future PE
75.67x
Price in 2028
AU$4.94
Automated Disinfection Solutions Will Transform Hospital Safety Worldwide
Key Takeaways Expansion of automated disinfection solutions and next-generation product launches are driving adoption, recurring revenue, and higher margins globally. Scalable operations and investment in innovation position the company for sustained earnings and margin growth as its product and geographic footprint expands.Read more
127
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
23users have followed this narrative
AN
AU$4.75
12.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
9.85% p.a.
Profit Margin
13.75%
Future PE
47.86x
Price in 2028
AU$5.83
Trending Discussion
Recently Updated Narratives
AN
NAN: Share Buyback Will Signal Confidence While Fair Value Suggests Upside
Fair Value: AU$5.43 23.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NAN: Share Buyback And Modest Margin Outlook Will Shape Future Performance
Fair Value: AU$4 3.5% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Automated Disinfection Solutions Will Transform Hospital Safety Worldwide
Fair Value: AU$4.75 12.8% undervalued intrinsic discount
23 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nanosonics Limited Key Details
About NAN
- Founded
- 2000
- Employees
- 470
- CEO
- WebsiteView website
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
